Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.55 |
| ▸ | MAG | P20916 | 7/20 | 0.47 |
| ▸ | SELL | P14151 | 1/20 | 0.44 |
| ▸ | SELP | P16109 | 1/20 | 0.44 |
| ▸ | SELE | P16581 | 4/20 | 0.41 |
| ▸ | CD22 | P20273 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18163357 | 0.93 | SIGLEC7 (0.51) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL18160541 | 0.93 | SIGLEC7 (0.56) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL18163348 | 0.88 | SIGLEC7 (0.59) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL18162217 | 0.88 | SIGLEC7 (0.61) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL18163345 | 0.88 | SIGLEC7 (0.61) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL19489048 | 0.84 | SIGLEC7 (0.54) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL16788602 | 0.84 | SIGLEC7 (0.62) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL17988584 | 0.82 | SELP (0.54) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL18166182 | 0.82 | SIGLEC7 (0.54) | SIGLEC7MAGSELLSELPSELE | |
| SCHEMBL18163344 | 0.82 | SIGLEC7 (0.54) | SIGLEC7MAGSELLSELPSELE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160303227-A1 | ANTI-GANGLIOSIDE COMPOUND FOR TARGETING CANCER AND GENERATING ANTIBODIES | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303227-A1 | ANTI-GANGLIOSIDE COMPOUND FOR TARGETING CANCER AND GENERATING ANTIBODIES | B3GAT3, ST6GAL1, STT3A | SIGLEC7 4/4885MAG 55/4885SELL 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.